Anaphylaxis Epidemiology Forecast 2026-2035

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Country

Japan

High-Risk Population

Individuals with previous anaphylaxis, food allergies, asthma, mast-cell disorders, cardiovascular disease, or exposure to known allergens

Key Diagnostic Method

Clinical assessment supported by serum tryptase and allergological testing when indicated

Major Risk Factor

Previous severe allergic reaction and re-exposure to the causative allergen

Major gap in the market

Delayed recognition, inconsistent diagnosis, and suboptimal epinephrine administration

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

According to Chaaban et al., 462,906 anaphylaxis cases were identified in the United States between 2004 and 2016, with incidence increasing from 153 to 218 cases per 100,000 population during the study period. The authors also identified substantial variation according to age, sex, and trigger.

Gender-Specific Cases of the Disease

According to Chaaban et al., females were more likely than males to experience anaphylaxis, with a female-to-male incidence rate ratio of approximately 1.19 in the U.S. population-based analysis. Sex differences vary by age and trigger, however, and should not be generalized across all forms of anaphylaxis.

Age-Specific Cases of the Disease

Anaphylaxis occurs across all age groups, but its epidemiology differs substantially with age. Children and adolescents have a particularly important burden of food-induced anaphylaxis, whereas medications and insect venom account for a greater proportion of reactions among adults. The U.S. population-based study demonstrated significant age-related variation in incidence and causative agents.

Ethnicity-Wise Cases of the Disease

Available epidemiological evidence indicates that anaphylaxis occurs across diverse ethnic populations, but reliable ethnicity-specific prevalence estimates remain limited. Differences in food exposure, genetic susceptibility, healthcare access, diagnostic practices, and reporting systems can influence observed rates. Consequently, ethnicity should not be presented as a single established epidemiological risk category without specifying the population and trigger.

Mortality and Survival Analysis of the Disease

Anaphylaxis is potentially fatal, but fatal outcomes are uncommon relative to the overall number of reactions. Mortality varies considerably according to trigger, age, comorbidities, and treatment delay. According to Turner et al., fatal anaphylaxis remains rare in population-level studies, while older age, cardiovascular disease, asthma, and delayed or inadequate epinephrine treatment can contribute to severe outcomes.

Disease Type

Prevalence

Food-Induced Anaphylaxis

Food is a major trigger of anaphylaxis, particularly in children. Important triggers include peanut, tree nuts, milk, egg, wheat, and shellfish, although the distribution differs by geography and age. Contemporary Asian surveillance demonstrates substantial variation in food triggers between countries, highlighting regional differences in allergen exposure and dietary patterns.

Drug-Induced Anaphylaxis

Drug-induced anaphylaxis is a major subtype, particularly among adults and in hospital or perioperative settings. In the U.S., medication-induced anaphylaxis increased approximately 15-fold during 2004–2016. Japanese pharmacovigilance data identified 16,916 reported drug-induced anaphylaxis cases and 418 fatalities between 2005 and 2017; diagnostic agents and biological preparations were frequent causes.

Venom-Induced Anaphylaxis

Hymenoptera venom, including bee and wasp venom, represents an important trigger, particularly among adults. European registry data demonstrate substantial venom-associated disease and fatality, supporting specialist evaluation and venom immunotherapy for appropriately selected patients.

Idiopathic and Other Anaphylaxis

A proportion of reactions remain without an identifiable trigger after appropriate evaluation and are classified as idiopathic anaphylaxis. Other clinically recognized categories include perioperative, exercise-associated, vaccine-associated, allergen-immunotherapy-associated, and pregnancy-associated anaphylaxis. Current practice guidance recommends additional evaluation in selected patients with recurrent or unexplained severe reactions.

Country

Key Insights

United States

According to Chaaban et al., 462,906 anaphylaxis cases were identified in a U.S. database between 2004 and 2016. Incidence increased from 153 to 218 per 100,000 population, while women were 1.19 times more likely than men to present with anaphylaxis. Medication-induced anaphylaxis increased 15-fold during the study period, highlighting the growing burden of drug-related anaphylaxis in the United States.

Germany

Germany is a major contributor to the European Anaphylaxis Registry and has generated substantial evidence concerning fatal and near-fatal anaphylaxis. European registry analyses identify food, drugs, and insect venom among the principal triggers, with trigger distribution strongly influenced by age and clinical setting.

France

According to Tanno et al., 2024, analysis of French hospitalization data from 2012–2021 found an average hospitalization rate for anaphylaxis of 1.34 per 100,000 population per year, while severe anaphylaxis admissions occurred at 0.08 per 100,000 per year. Among severe cases with an identified trigger, drugs accounted for 45.6%, followed by food at 9.3% and insect stings at 7.2%.

Italy

Italy has contributed to European evidence on anaphylaxis and fatal hypersensitivity reactions, although a directly comparable contemporary national all-cause incidence estimate is not sufficiently established to justify a single figure. European registry evidence remains useful for characterizing trigger-specific risk and mortality.

Spain

Spain contributes to European anaphylaxis surveillance and published fatality analyses. However, available studies differ in population, trigger, and ascertainment methodology; therefore, a single contemporary national incidence figure should not be presented without specifying the underlying dataset.

United Kingdom

The United Kingdom has established national surveillance and has contributed substantially to the epidemiological characterization of anaphylaxis. However, incidence estimates vary according to whether emergency presentations, hospital admissions, or clinically confirmed episodes are measured; consequently, estimates should be reported with their specific study methodology.

Japan

According to Japanese nationwide pharmacovigilance data, 16,916 anaphylaxis cases and 418 fatalities were reported between 2005 and 2017. Drug-induced anaphylaxis occurred at an estimated 1.03 cases per 100,000 population per year, while fatal cases occurred at approximately 0.03 per 100,000 per year. Diagnostic agents and biological preparations were frequent causes.

India

India has a clinically important but incompletely quantified anaphylaxis burden. Available evidence is dominated by hospital-based studies, case series, and trigger-specific investigations rather than comprehensive national surveillance. Therefore, a precise contemporary national incidence or prevalence estimate should not be stated without a clearly defined population-based source.